Christopher Lieu, MD, of the University of Colorado Anschutz Cancer Center says daraxonrasib shows real promise for pancreatic cancer patients, while cautioning that outcomes and side effects remain uncertain.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045